BR105, combined with the CD20 antibody or the HER-2 antibody in vitro, could promote macrophage phagocytosis of CD20-positive Burkitt lymphoma cells or SK-BR-3 breast cancer cells, overexpressing HER-2. The gene discussed is ERBB2; the disease is breast carcinoma.